Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Ischemic Stroke Undergoing Endovascular Treatment
NCT06238024Phase 3Completed
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Feb 2024
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in ischemic stroke, sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Started Feb 2024; status: completed.
02
Drugs
tocilizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06238024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238024.